A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder

Study Identifier:

405-201-00016

ClinicalTrials.gov Identifier:

NCT05257265

EudraCT Identifier:

N/A

EU CT ID:

N/A

Study Contact Information:

N/A

Study Complete

Subscribe to Updates

Study Details

Medical Condition

ADHD

Study Drug

Drug: Centanafadine Hydrochloride

Date

Feb 2022 - Sep 2023

Phase 1/2

Phase 2/3

Phase 1

Phase 2

Phase 3

Phase 4

N/A

Patient Requirements

Sex: Female & Male

Age: 13 - 17 Years

Requirements Information

Protocol Summary

This trial was conducted to evaluate the efficacy and safety of the Centanafadine once daily (QD) extended release (XR) capsules in adolescent participants (13 - 17 years, inclusive) with attention-deficit/hyperactivity disorder (ADHD).

Study Locations

Location

Status

Location

For additional information regarding sites, contact 844-687-8522

New York, New York, United States, 10012

Status

N/A